Epizyme traded at $1.47 this Thursday August 11th, decreasing $0.02 or 1.34 percent since the previous trading session. Looking back, over the last four weeks, Epizyme lost 1.34 percent. Over the last 12 months, its price fell by 72.88 percent. Looking ahead, we forecast Epizyme to be priced at 1.48 by the end of this quarter and at 1.36 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 6,115.00 20.00 0.33% -33.38%
Daiichi Sankyo 3,677.00 45.00 1.24% 60.11%
Abbott 111.48 0.99 0.90% -9.41%
Agios Pharmaceuticals 28.15 2.16 8.31% -35.95%
Amgen 248.39 0.04 0.02% 8.15%
Amarin 1.65 0.04 2.48% -69.56%
Avrobio Inc 1.07 0.03 2.88% -82.08%
Biogen 220.99 2.77 1.27% -35.43%
Bluebird Bio 6.72 0.41 6.50% -63.62%
Epizyme 1.47 -0.02 -1.34% -72.88%
Exelixis 19.48 0.25 1.30% 6.56%
Gilead Sciences 62.96 0.51 0.82% -11.52%
GlaxoSmithKline 1,450.00 50.00 3.57% -2.80%
Glaxosmithkline 36.03 0.30 0.84% -14.15%
Ionis Pharmaceuticals 44.10 0.66 1.52% 11.14%
Karyopharm Therapeutics 5.41 0.45 9.07% 10.86%
MacroGenics 5.22 0.13 2.55% -77.49%
Merck & Co 91.02 2.09 2.35% 18.64%
Mirati Therapeutics 86.37 5.92 7.36% -38.38%
Novartis 80.10 -0.94 -1.16% -6.82%
Novartis 85.68 0.10 0.12% -8.69%
Pfizer 50.11 1.82 3.77% 3.36%
Regeneron Pharmaceuticals 628.71 4.81 0.77% 0.63%
Seattle Genetics 170.14 -3.90 -2.24% 8.76%
Spectrum Pharmaceuticals 1.36 0.15 12.40% -39.82%
Vertex Pharmaceuticals 294.52 2.36 0.81% 51.53%
Xencor 30.47 1.81 6.32% -5.49%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%
US2000 2017 41.36 2.09% -9.29%

Epizyme
Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization epigenetic treatment for people with cancer and other serious diseases. The Company’s lead product candidate TAZVERIK (tazemetostat) is an oral selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT). AZVERIK is available to the eligible patients and their physicians in the United States through a specialty distribution network. The Company is developing tazemetostat for the treatment of a range of cancer types in multiple treatment settings. Tazemetostat is a pipeline product, which is showing clinical activity as an investigational monotherapy in multiple cancer indications.